FDA hands ap­proval to Janssen's BR­CA-pos­i­tive prostate can­cer com­bo tablet

John­son & John­son’s Janssen scored an FDA ap­proval with its li­censed PARP in­hibitor ni­ra­parib in com­bi­na­tion with abi­raterone ac­etate for the treat­ment of BR­CA-pos­i­tive metasta­t­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER